Putting GSK’s China Bribery Crisis In Context
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK’s China bribery crisis stems in part from a poorly managed and financed public-hospital system that relies on drug sales and markups to survive. The question is, will the government make reforms soon enough, and what should companies do in the meantime?
You may also be interested in...
China Executes Former Food And Drug Head
China executed Zheng Xiaouy, the former head of the State Food and Drug Administration, July 10 for dereliction of duty and for accepting $850,000 worth of bribes from pharmaceutical companies, according to the official Xinhua news service
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.